IBIO advances AI obesity antibody pipeline to clinic
IBIO’s AI-driven obesity antibody pipeline advanced to clinic as net loss rose, with liquidity still described as strong.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.